MedTrace Logo

Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes

NCT02721537 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-08-03

No results posted yet for this study

Summary

Can nicotinamide riboside (750 mg/day for 12 weeks) affect the levels of NAD+ in the brain as measured by 31P MRS?

Conditions

  • Concussion, Mild

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside

Three capsules, twice per day for 84 days

OTHER

Matching placebo

Three matching capsules, twice per day for 84 days

Sponsors & Collaborators

Principal Investigators

  • Brent A Bauer, MD · Mayo Clinic in Rochester, MN

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02721537 on ClinicalTrials.gov